Appl. No. 10/516,450

Amdt. dated November 15, 2007

Reply to Office Action of October 18, 2007

**Amendments to the Claims:** 

This listing of claims will replace all prior versions, and listings, of claims in

the application:

**Listing of Claims:** 

Claim 1 (currently amended): A method of blocking or reducing access to a

procoagulant membrane by a coagulation molecule, comprising;

a) providing a procoagulant membrane including a binding site

containing phosphatidylserine phosphatidyl-L-serine; and

b) blocking the binding site of the procoagulant membrane by binding

lactadherin thereto thereby making the site unavailable for interaction

by a coagulation molecule.

Claim 2 (previously amended): The method of Claim 1, wherein:

a biological particle comprises the procoagulant membrane, the

biological particle comprises at least one member selected from the

group consisting of a platelet, a apoptotic cell, a necrotic cell, a blood

cell, and a vascular cell.

Page 3 of 6

Appl. No. 10/516,450

Amdt. dated November 15, 2007

Reply to Office Action of October 18, 2007

Claim 3 (previously amended): The method of Claim 1, wherein:

the procoagulant membrane comprises a phospholipid or a lipoprotein.

Claim 4 (original): The method of Claim 3, wherein:

the coagulation molecule comprises a blood coagulation protein.

Claim 5 (previously amended): The method of Claim 3, wherein:

Claim 6 (currently amended): The method of Claim 2, wherein:

the blood cell comprises a lymphocyte, a monocyte, a neutrophil, or an erythrocyte that has been stimulated or stressed to expose <a href="https://phosphatidylserine">phosphatidyl-L-serine</a>.

Claims 7-19 (cancelled).